Table 3.

Baseline characteristics of bosentan-treated patients and historical controls.

CharacteristicBosentan-treated Patients, n = 9Controls, n = 17p
Years at study entry2006–20071988–2006
Age at study entry, yrs*55.1 ± 19.054.3 ± 11.80.9
Women, %56710.7
Disease duration, mo*141 ± 134109 ± 520.4
Diffuse cutaneous SSc, %56880.3
Extensive disease (ILD staging), %891000.7
% FVC*58.2 ± 24.450.8 ± 6.30.3
% DLCO31.2 ± 12.531.1 ± 6.51.0
Oxygen supplementation, %44410.8
Pulmonary hypertension, %11180.9
Antitopoisomerase I antibody, %56820.3
Anti-U1RNP antibody, %33120.4
  • * Results are mean ± SD.